Research opens doors to the future of cancer treatment

We use clinical trials to find better ways to treat cancer. Your participation in a study can give you early access to groundbreaking drugs or therapies that most cancer centers can't offer.
 
Dozens of clinical studies are currently underway at Goshen Center for Cancer Care. Use our list of cancer types to search for studies that are open for enrollment by qualified patients.
 
Descriptions about each study explain the purpose of the trial, who is eligible to participate and how to get more information.
 
ClinicalTrials.gov maintains a complete list of current clinical trials around the world.

Cancer care close to home

Our dedicated team of oncologists and cancer care specialists at Goshen Center for Cancer Care offer world-renowned care with a hometown touch. Your team of cancer experts is prepared to stand beside you every step of the way, from diagnosis and treatment to recovery and beyond.
 
You are at the center of everything we do while you are in our care. Our integrative approach means we design a treatment program specifically for you and your needs. It's how we empower you when you need it most.
 
We believe a second opinion about your diagnosis can be life changing. A thorough evaluation may help provide a clear path for your treatment and give you peace of mind.

Get a Second Opinion

We can help

Find out if a clinical trial is right for you. Talk with our oncology experts about studies that offer patients early access to drugs approved by the Food and Drug Administration.
 
Goshen Center for Cancer Care
200 High Park Avenue
Goshen IN 46526
(888) 492-HOPE
gcccresearch@goshenhealth.com

  • Breast Cancer

    Advanced Malignancies: Mirati 516-010
    Sponsor: Mirati Therapeutics
    Study: 516-010
    Cancer Stage: Advanced Solid Metastatic Malignancies

    Description: A Two-cohort, Two-part, Phase 1, Multicenter, Open-label, Fixed-sequence, Drug-Drug Interaction and QTc Assessments of Sitravatinib Followed by Combination Treatment with Nivolumab in Patients with Advanced Solid Malignancies (NCT# 04887194)

    Inclusions: 

    • Histologically or cytologically confirmed diagnosis of unresectable advanced/metastatic
      solid tumor malignancy
    • No available treatment with curative intent, or No available standard-of-care (SOC) treatment or patient is ineligible or declines treatment

    Exclusions:

    Prior treatment:

    Purpose: 

    • This is a two-cohort, two-part, Phase 1, multicenter, open-label, nonrandomized, fixed-sequence study in patients with advanced/metastatic solid tumors. The DDI cohort, Part 1, is designed to evaluate the potential for drug interactions with sitravatinib monotherapy and to collect ECG data for QTc analysis (CCC is not participating in the DDI cohort). The QTc cohort, Part 1, is designed to evaluate the effect of sitravatinib on QTc. Concentration and QTc data collected from both DDI and QTc cohorts will be used for C-QTc modeling. Part 2 allows for patients from both cohorts to continue sitravatinib treatment with the addition of the checkpoint inhibitor nivolumab.

    Basic Qualifications:

    Breast Cancer: A221702
    Sponsor: Alliance
    Study: Breast Cancer: A221702
    Cancer Stage: Invasive Breast Cancer

    Description:

    Inclusions: 

    • Invasive breast cancer that requires staging of your lymph nodes in your armpit area. 
    • In order to complete the mandatory patient-completed forms, participants must be able to speak and/or read English.       

    Exclusions: 

    • No prior axillary sugery. 
    • No history of lymphedema of either arm. 
    • No prior history of ipsilateral breast cancer.

    Prior treatment: 

    • Prior treatment not required

    Purpose: 

    • To find out if an added procedure during your breast cancer surgery is better than the usual approach for reducing the chance of developing swelling in the arm.

    Basic Qualifications:  

    • Invasive breast cancer that requires staging of your lymph nodes in your armpit area
  • Bladder Cancer

    Advanced Malignancies: Mirati 516-010
    Sponsor: Mirati Therapeutics
    Study: 516-010
    Cancer Stage: Advanced Solid Metastatic Malignancies

    Description: A Two-cohort, Two-part, Phase 1, Multicenter, Open-label, Fixed-sequence, Drug-Drug Interaction and QTc Assessments of Sitravatinib Followed by Combination Treatment with Nivolumab in Patients with Advanced Solid Malignancies (NCT# 04887194)

    Inclusions: 

    • Histologically or cytologically confirmed diagnosis of unresectable advanced/metastatic
      solid tumor malignancy
    • No available treatment with curative intent, or No available standard-of-care (SOC) treatment or patient is ineligible or declines treatment

    Exclusions:

    Prior treatment:

    Purpose: 

    • This is a two-cohort, two-part, Phase 1, multicenter, open-label, nonrandomized, fixed-sequence study in patients with advanced/metastatic solid tumors. The DDI cohort, Part 1, is designed to evaluate the potential for drug interactions with sitravatinib monotherapy and to collect ECG data for QTc analysis (CCC is not participating in the DDI cohort). The QTc cohort, Part 1, is designed to evaluate the effect of sitravatinib on QTc. Concentration and QTc data collected from both DDI and QTc cohorts will be used for C-QTc modeling. Part 2 allows for patients from both cohorts to continue sitravatinib treatment with the addition of the checkpoint inhibitor nivolumab.

    Basic Qualifications:

    Advanced Malignancies: ARCUS ARC-12
    Sponsor: ARCUS
    Study: Advanced Malignancies: ARCUS ARC-12
    Cancer Stage: Advanced

    Description: A phase 1/1b study to evaluate the safety and tolerability of AB308 in combination with AB122 in advanced malignancies

    Inclusions: 

    • Participants may have any pathologically confirmed solid tumor type for which no standard of care therapy exists
    • or pathologically confirmed NHL who are refractory or have relapsed on prior chemotherapy regimen and who have not received or are unable to receive allogenic stem cell transplant (ASCT) or adoptive cell transfer (ACT)
    • Participants may have received up to and including 5 lines of prior systemic anti-cancer therapies for advanced/recurrent and PD (an unlimited number of prior hormonal therapies) is allowed

    Exclusions: 

    • Treatment with systemic immunosuppressive medication
    • Prior treatment with an anti-TIGIT monoclonal antibody

    Prior treatment: 

    • Up to and including 5 lines of prior systemic anti-cancer therapies

    Purpose: 

    • To evaluate the safety, tolerability, PK, pharmacodynamics, and clinical activity of AB308 (anti-TIGIT inhibitor) in combination with zimberelimab (PD-1 inhibitor)

    Basic Qualifications: 

  • Colon and Rectum Cancer

    Advanced Malignancies: Mirati 516-010
    Sponsor: Mirati Therapeutics
    Study: 516-010
    Cancer Stage: Advanced Solid Metastatic Malignancies

    Description: A Two-cohort, Two-part, Phase 1, Multicenter, Open-label, Fixed-sequence, Drug-Drug Interaction and QTc Assessments of Sitravatinib Followed by Combination Treatment with Nivolumab in Patients with Advanced Solid Malignancies (NCT# 04887194)

    Inclusions: 

    • Histologically or cytologically confirmed diagnosis of unresectable advanced/metastatic
      solid tumor malignancy
    • No available treatment with curative intent, or No available standard-of-care (SOC) treatment or patient is ineligible or declines treatment

    Exclusions:

    Prior treatment:

    Purpose: 

    • This is a two-cohort, two-part, Phase 1, multicenter, open-label, nonrandomized, fixed-sequence study in patients with advanced/metastatic solid tumors. The DDI cohort, Part 1, is designed to evaluate the potential for drug interactions with sitravatinib monotherapy and to collect ECG data for QTc analysis (CCC is not participating in the DDI cohort). The QTc cohort, Part 1, is designed to evaluate the effect of sitravatinib on QTc. Concentration and QTc data collected from both DDI and QTc cohorts will be used for C-QTc modeling. Part 2 allows for patients from both cohorts to continue sitravatinib treatment with the addition of the checkpoint inhibitor nivolumab.

    Basic Qualifications:

    Colon: NRG-GI005
    Sponsor: NRG Oncology
    Study: Colon: NRG-GI005
    Cancer Stage: Stage IIA

    Description:

    Inclusions: 

    • Stage IIA adenocarcinoma of the colon with at least 12 lymph nodes examined at the time of surgical resection
    • Appropriate for active surveillance (i.e., no adjuvant chemotherapy) at the discretion of and as documented by the evaluating oncologist based on current practice patterns
    • The distal extent of the tumor must be >= 12 cm from the anal verge on pre-surgical endoscopy 
    • ECOG performance status of 0 or 1

    Exclusions: 

    • Colon cancer histology other than adenocarcinoma (i.e., neuroendocrine carcinoma, sarcoma, lymphoma, squamous cell carcinoma, etc.)
    • Pathologic, clinical, or radiologic evidence of metastatic disease

    Prior treatment: 

    • Yes, prior surgery is required

    Purpose: 

    • This phase II/III trial studies how well circulating tumor deoxyribonucleic acid (ctDNA) testing in the blood works in predicting treatment for patients with stage IIA colon cancer after surgery

    Basic Qualifications:

    • Stage IIA adenocarcinoma of the colon with at least 12 lymph nodes examined at the time of surgical resection
    • Appropriate for active surveillance (i.e., no adjuvant chemotherapy) at the discretion of and as documented by the evaluating oncologist based on current practice patterns
  • Esophageal and Stomach Cancer

    Advanced Malignancies: Mirati 516-010
    Sponsor: Mirati Therapeutics
    Study: 516-010
    Cancer Stage: Advanced Solid Metastatic Malignancies

    Description: A Two-cohort, Two-part, Phase 1, Multicenter, Open-label, Fixed-sequence, Drug-Drug Interaction and QTc Assessments of Sitravatinib Followed by Combination Treatment with Nivolumab in Patients with Advanced Solid Malignancies (NCT# 04887194)

    Inclusions: 

    • Histologically or cytologically confirmed diagnosis of unresectable advanced/metastatic
      solid tumor malignancy
    • No available treatment with curative intent, or No available standard-of-care (SOC) treatment or patient is ineligible or declines treatment

    Exclusions:

    Prior treatment:

    Purpose: 

    • This is a two-cohort, two-part, Phase 1, multicenter, open-label, nonrandomized, fixed-sequence study in patients with advanced/metastatic solid tumors. The DDI cohort, Part 1, is designed to evaluate the potential for drug interactions with sitravatinib monotherapy and to collect ECG data for QTc analysis (CCC is not participating in the DDI cohort). The QTc cohort, Part 1, is designed to evaluate the effect of sitravatinib on QTc. Concentration and QTc data collected from both DDI and QTc cohorts will be used for C-QTc modeling. Part 2 allows for patients from both cohorts to continue sitravatinib treatment with the addition of the checkpoint inhibitor nivolumab.

    Basic Qualifications:

    Advanced Malignancies: ARCUS ARC-12
    Sponsor: ARCUS
    Study: Advanced Malignancies: ARCUS ARC-12
    Cancer Stage: Advanced

    Description: A phase 1/1b study to evaluate the safety and tolerability of AB308 in combination with AB122 in advanced malignancies

    Inclusions: 

    • Participants may have any pathologically confirmed solid tumor type for which no standard of care therapy exists
    • or pathologically confirmed NHL who are refractory or have relapsed on prior chemotherapy regimen and who have not received or are unable to receive allogenic stem cell transplant (ASCT) or adoptive cell transfer (ACT)
    • Participants may have received up to and including 5 lines of prior systemic anti-cancer therapies for advanced/recurrent and PD (an unlimited number of prior hormonal therapies) is allowed

    Exclusions: 

    • Treatment with systemic immunosuppressive medication
    • Prior treatment with an anti-TIGIT monoclonal antibody

    Prior treatment: 

    • Up to and including 5 lines of prior systemic anti-cancer therapies

    Purpose: 

    • To evaluate the safety, tolerability, PK, pharmacodynamics, and clinical activity of AB308 (anti-TIGIT inhibitor) in combination with zimberelimab (PD-1 inhibitor)

    Basic Qualifications: 

  • Gynecologic Cancer

    Gynecologic: NRG-GY019
    Sponsor: NRG Oncology
    Study: GY019
    Cancer Stage: Stage II-IV

    Description: A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum (NCT#04095364)

    Inclusions:

    • Newly diagnosed Stage II-IV ovarian cancer
    • Must have undergone an attempt at maximal upfront cytoreductive surgery and bilateral salpingo-oophorectomy

    Exclusions:

    • May not have received neoadjuvant chemotherapy or radiotherapy and no previous hormonal therapy for the treatment of this disease

    Prior treatment:

    • None

    Purpose:

    • To examine if letrozole monotherapy/maintenance (L/L) is non-inferior to IV paclitaxel/carboplatin and maintenance letrozole (CT/L) with respect to PFS in women with stage II-IV primary low-grade serous carcinoma of the ovary or peritoneum after primary surgical cytoreduction.

    Basic Qualifications:

    • Same as inclusion criteria
  • Head and Neck Cancer

    Advanced Malignancies: Mirati 516-010
    Sponsor: Mirati Therapeutics
    Study: 516-010
    Cancer Stage: Advanced Solid Metastatic Malignancies

    Description: A Two-cohort, Two-part, Phase 1, Multicenter, Open-label, Fixed-sequence, Drug-Drug Interaction and QTc Assessments of Sitravatinib Followed by Combination Treatment with Nivolumab in Patients with Advanced Solid Malignancies (NCT# 04887194)

    Inclusions: 

    • Histologically or cytologically confirmed diagnosis of unresectable advanced/metastatic
      solid tumor malignancy
    • No available treatment with curative intent, or No available standard-of-care (SOC) treatment or patient is ineligible or declines treatment

    Exclusions:

    Prior treatment:

    Purpose: 

    • This is a two-cohort, two-part, Phase 1, multicenter, open-label, nonrandomized, fixed-sequence study in patients with advanced/metastatic solid tumors. The DDI cohort, Part 1, is designed to evaluate the potential for drug interactions with sitravatinib monotherapy and to collect ECG data for QTc analysis (CCC is not participating in the DDI cohort). The QTc cohort, Part 1, is designed to evaluate the effect of sitravatinib on QTc. Concentration and QTc data collected from both DDI and QTc cohorts will be used for C-QTc modeling. Part 2 allows for patients from both cohorts to continue sitravatinib treatment with the addition of the checkpoint inhibitor nivolumab.

    Basic Qualifications:

  • Kidney Cancer

    Advanced Malignancies: Mirati 516-010
    Sponsor: Mirati Therapeutics
    Study: 516-010
    Cancer Stage: Advanced Solid Metastatic Malignancies

    Description: A Two-cohort, Two-part, Phase 1, Multicenter, Open-label, Fixed-sequence, Drug-Drug Interaction and QTc Assessments of Sitravatinib Followed by Combination Treatment with Nivolumab in Patients with Advanced Solid Malignancies (NCT# 04887194)

    Inclusions: 

    • Histologically or cytologically confirmed diagnosis of unresectable advanced/metastatic
      solid tumor malignancy
    • No available treatment with curative intent, or No available standard-of-care (SOC) treatment or patient is ineligible or declines treatment

    Exclusions:

    Prior treatment:

    Purpose: 

    • This is a two-cohort, two-part, Phase 1, multicenter, open-label, nonrandomized, fixed-sequence study in patients with advanced/metastatic solid tumors. The DDI cohort, Part 1, is designed to evaluate the potential for drug interactions with sitravatinib monotherapy and to collect ECG data for QTc analysis (CCC is not participating in the DDI cohort). The QTc cohort, Part 1, is designed to evaluate the effect of sitravatinib on QTc. Concentration and QTc data collected from both DDI and QTc cohorts will be used for C-QTc modeling. Part 2 allows for patients from both cohorts to continue sitravatinib treatment with the addition of the checkpoint inhibitor nivolumab.

    Basic Qualifications:

    Advanced Malignancies: ARCUS ARC-12
    Sponsor: ARCUS
    Study: Advanced Malignancies: ARCUS ARC-12
    Cancer Stage: Advanced

    Description: A phase 1/1b study to evaluate the safety and tolerability of AB308 in combination with AB122 in advanced malignancies

    Inclusions: 

    • Participants may have any pathologically confirmed solid tumor type for which no standard of care therapy exists
    • or pathologically confirmed NHL who are refractory or have relapsed on prior chemotherapy regimen and who have not received or are unable to receive allogenic stem cell transplant (ASCT) or adoptive cell transfer (ACT)
    • Participants may have received up to and including 5 lines of prior systemic anti-cancer therapies for advanced/recurrent and PD (an unlimited number of prior hormonal therapies) is allowed

    Exclusions: 

    • Treatment with systemic immunosuppressive medication
    • Prior treatment with an anti-TIGIT monoclonal antibody

    Prior treatment: 

    • Up to and including 5 lines of prior systemic anti-cancer therapies

    Purpose: 

    • To evaluate the safety, tolerability, PK, pharmacodynamics, and clinical activity of AB308 (anti-TIGIT inhibitor) in combination with zimberelimab (PD-1 inhibitor)

    Basic Qualifications: 

  • Liver Cancer

    Advanced Malignancies: Mirati 516-010
    Sponsor: Mirati Therapeutics
    Study: 516-010
    Cancer Stage: Advanced Solid Metastatic Malignancies

    Description: A Two-cohort, Two-part, Phase 1, Multicenter, Open-label, Fixed-sequence, Drug-Drug Interaction and QTc Assessments of Sitravatinib Followed by Combination Treatment with Nivolumab in Patients with Advanced Solid Malignancies (NCT# 04887194)

    Inclusions: 

    • Histologically or cytologically confirmed diagnosis of unresectable advanced/metastatic
      solid tumor malignancy
    • No available treatment with curative intent, or No available standard-of-care (SOC) treatment or patient is ineligible or declines treatment

    Exclusions:

    Prior treatment:

    Purpose: 

    • This is a two-cohort, two-part, Phase 1, multicenter, open-label, nonrandomized, fixed-sequence study in patients with advanced/metastatic solid tumors. The DDI cohort, Part 1, is designed to evaluate the potential for drug interactions with sitravatinib monotherapy and to collect ECG data for QTc analysis (CCC is not participating in the DDI cohort). The QTc cohort, Part 1, is designed to evaluate the effect of sitravatinib on QTc. Concentration and QTc data collected from both DDI and QTc cohorts will be used for C-QTc modeling. Part 2 allows for patients from both cohorts to continue sitravatinib treatment with the addition of the checkpoint inhibitor nivolumab.

    Basic Qualifications:

  • Lung Cancer

    Advanced Malignancies: Mirati 516-010
    Sponsor: Mirati Therapeutics
    Study: 516-010
    Cancer Stage: Advanced Solid Metastatic Malignancies

    Description: A Two-cohort, Two-part, Phase 1, Multicenter, Open-label, Fixed-sequence, Drug-Drug Interaction and QTc Assessments of Sitravatinib Followed by Combination Treatment with Nivolumab in Patients with Advanced Solid Malignancies (NCT# 04887194)

    Inclusions: 

    • Histologically or cytologically confirmed diagnosis of unresectable advanced/metastatic
      solid tumor malignancy
    • No available treatment with curative intent, or No available standard-of-care (SOC) treatment or patient is ineligible or declines treatment

    Exclusions:

    Prior treatment:

    Purpose: 

    • This is a two-cohort, two-part, Phase 1, multicenter, open-label, nonrandomized, fixed-sequence study in patients with advanced/metastatic solid tumors. The DDI cohort, Part 1, is designed to evaluate the potential for drug interactions with sitravatinib monotherapy and to collect ECG data for QTc analysis (CCC is not participating in the DDI cohort). The QTc cohort, Part 1, is designed to evaluate the effect of sitravatinib on QTc. Concentration and QTc data collected from both DDI and QTc cohorts will be used for C-QTc modeling. Part 2 allows for patients from both cohorts to continue sitravatinib treatment with the addition of the checkpoint inhibitor nivolumab.

    Basic Qualifications:

    Advanced Malignancies: ARCUS ARC-12
    Sponsor: ARCUS
    Study: Advanced Malignancies: ARCUS ARC-12
    Cancer Stage: Advanced

    Description: A phase 1/1b study to evaluate the safety and tolerability of AB308 in combination with AB122 in advanced malignancies

    Inclusions: 

    • Participants may have any pathologically confirmed solid tumor type for which no standard of care therapy exists
    • or pathologically confirmed NHL who are refractory or have relapsed on prior chemotherapy regimen and who have not received or are unable to receive allogenic stem cell transplant (ASCT) or adoptive cell transfer (ACT)
    • Participants may have received up to and including 5 lines of prior systemic anti-cancer therapies for advanced/recurrent and PD (an unlimited number of prior hormonal therapies) is allowed

    Exclusions: 

    • Treatment with systemic immunosuppressive medication
    • Prior treatment with an anti-TIGIT monoclonal antibody

    Prior treatment: 

    • Up to and including 5 lines of prior systemic anti-cancer therapies

    Purpose: 

    • To evaluate the safety, tolerability, PK, pharmacodynamics, and clinical activity of AB308 (anti-TIGIT inhibitor) in combination with zimberelimab (PD-1 inhibitor)

    Basic Qualifications: 

    Lung: A151216 (ALCHEMIST Screen)
    Sponsor: Alliance
    Study: Lung: A151216 (ALCHEMIST Screen)
    Cancer Stage: Resectable NSCLC IB-IIIA

    Description:

    Inclusions: 

    • For post-surgical patients
    • Completely resected non-small cell lung cancer. Patients with squamous cell carcinoma are eligible.
    • Pathologic stage IIIA, II or IB (defined as size ≥4 cm) For all patients • ECOG Performance Status 0-1 • Age ≥ 18 years
    • No prior or concurrent malignancies within 5 years, except non-melanoma skin carcinoma or in situ carcinomas. A secondary primary lung cancer is considered a concurrent malignancy and would make a patient ineligible for A151216.• No prior treatment with agents targeting EGFR mutation, ALK rearrangement, and PD-1/PD-L1/CTLA-4.
    • Patients who have had local genotyping are eligible, regardless of the local result.
    • No patients with recurrence of lung cancer after prior resection. Patient Registration Eligibility Criteria
    • Pathologic stage IIIA, II, or large IB (defined as size ≥ 4cm)
    • Tissue available for the required analyses (either clinical tissue block or slides and scrolls)
    • In order to allow for time for central genotyping and eligibility for the ALCHEMIST treatment trial, patients must register within the following eligibility windows, depending on the adjuvant treatment approach:
    1. If no adjuvant therapy, register patient within 75 days following surgery.
    2. If adjuvant chemotherapy only, register patient within 225 days following surgery.
    3. If adjuvant chemotherapy and radiation, register patient within 285 days following surgery.

    Exclusions: 

    Prior treatment: 

    • No patients who have received neoadjuvant therapy (chemo- or radio-therapy) for this lung cancer.

    Purpose: 

    • This research trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been removed or will be removed by surgery.

    Basic Qualifications:

    • Completely resected (resectable) non-small cell lung cancer.
    • Patients with squamous cell carcinoma are eligible.

    Lung: LungMAP Screening
    Sponsor: SWOG
    Study: Lung: LungMAP Screening
    Cancer Stage: Stage IV NSCLC

    Description:

    Inclusions: 

    • Stage IV or recurrent NSCLC
    • Must have received at least one line of systemic therapy for any stage of disease (Stages I-IV) and must have progressed during or following their most recent line of therapy
    • Must have adequate tissue available and a sample submitted to Foundation Medicine for biomarker profiling
    • Must be willing to provide prior smoking history

    Exclusions: 

    • Patients with known EGFR sensitizing mutations, EGFR T790M mutation, ALK gene fusion, ROS 1 gene rearrangement, or BRAF V600E mutation are not eligible

    Prior treatment: 

    • Prior treatment is required: must have received at least one line of systemic therapy 

    Purpose: 

    • Pre-screening-to-sub-study assignment will be measured among pre-screened patients and the proportion of patients assigned to a sub-study

    Basic Qualifications 

    • Stage IV or recurrent NSCLC
    • Must have received at least one line of systemic therapy for any stage of disease (Stages I-IV) and must have progressed during or following their most recent line of therapy

    Lung: M14-239
    Sponsor: AbbVie
    Study: Lung: M14-239
    Cancer Stage: NSCLC

    Description:

    Inclusions:   

    •   Subjects must have locally advanced or metastatic NSCLC
    •   Subjects must have c-Met+NSCLC
    •   Subjects have an ECOG Performance Status of 0 or 1  
    •   Subjects must have received no more than 2 lines of prior systemic chemotherapy (including no more than 1 line of systemic cytotoxic chemotherapy) in the metastatic setting

    Exclusions: 

    • Subjects must not have a history of interstitial lung disease or pneumonitis      

    Prior treatment: 

    • Subjects must have received no more than 2 lines of prior systemic chemotherapy (including no more than 1 line of systemic cytotoxic chemotherapy) in the metastatic setting   

    Purpose: 

    • The primary objective is to determine the overall response rate (ORR) of telisotuzumab vedotin in subjects with c-Met+ NSCLC.

    Basic Qualifications: 

    •   Subjects must have locally advanced or metastatic NSCLC
    •   Subjects must have c-Met+NSCLC

    Lung: ANAM-17-20
    Sponsor: Helsinn
    Study: Lung: ANAM-17-20
    Cancer Stage: Stage III or IV

    Description:

    Inclusions: 

    • Stage III or IV NSCLC.
    • Stage III patient must have unresectable disease.
    • Body mass index < 20 kg/m2 with involuntary weight loss of >2% within 6 months prior to screening.
    • Ongoing problems with appetite/eating associated with the underlying cancer.
    • Patients receiving or not receiving systemic anti-cancer treatment at the time of screening are eligible to participate.

    Exclusions: 

    • Patients with other forms of lung cancer (e.g., small cell, neuroendocrine tumors.)
    • Reversible causes of reduced food intake, as determined by the Investigator.
    • Patients undergoing major surgery (central venous access placement and tumor biopsies are not considered major surgery) within 4 weeks prior to randomization.

    Prior treatment: 

    • Prior treatment is allowed but not required.

    Purpose: 

    • To demonstrate superiority of anamorelin vs placebo on the gain in body weight and improvement in anorexia symptoms.  

    Basic Qualifications:

    • Stage III or IV NSCLC. Stage III patient must have unresectable disease.
    • Body mass index < 20 kg/m2 with involuntary weight loss of >2% within 6 months prior to screening.

    Lung: JZP712-402
    Sponsor: Jazz Pharmaceuticals
    Study: Lung: JZP712-402
    Cancer Stage: Extensive Stage Small Cell Lung Cancer

    Description: Phase IV Observational Study to Collect Safety and Outcome Data in Adult Patients with Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca

    Inclusions: 

    • Patient has initiated or will be receiving Zepzelca treatment in line with the Zepzelca US prescribing information

    Exclusions: 

    • Patients who discontinued a prior Zepzelca treatment due to adverse events

    Prior treatment: 

    Purpose: 

    • This is a phase IV observational study designed to collect data on treatment with Zepzelca

    Basic Qualifications:

    • The treatment decision, decision to initiate Zepzelca, and overall patient management is entirely at the investigators’ discretion and should not be impacted by the conduct of this study

    Lung: E4512 (ALCHEMIST - ALK)
    Sponsor: ECOG-ACRIN
    Study: Lung: E4512 (ALCHEMIST - ALK)
    Cancer Stage: Resectable NSCLC IB-IIIA

    Description:

    Inclusions: 

    • Age ≥ 18 years.
    • Patients must have undergone complete surgical resection of their stage IB (≥ 4 cm), II, or non-squamous IIIA NSCLC and have had negative margins. N3 disease is not allowed.
    • ECOG performance status 0 or 1.
    • Positive for translocation or inversion events involving the ALK gene locus (e.g. resulting in EML4-ALK fusion) as determined by the Vysis Break Point FISH assay and defined by an increase in the distance between 5’ and 3’ ALK probes or the loss of the 5’ probe.
    • No known interstitial fibrosis or interstitial lung disease.
    • No use of medications, herbals, or foods that are known potent CYP3A4 inhibitors or inducers.
    • Patients must not have any history of cancer within 5 years from randomization, with the exception of in-situ carcinomas and non-melanoma skin cancer.

    Exclusions: 

    Prior treatment: 

    • Adjuvant treatment is allowed. No prior treatment with crizotinib or another ALK inhibitor.

    Purpose: 

    • This randomized phase III trial studies how well crizotinib works and compares it to placebo in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.

    Basic Qualifications:

    • Patients must be registered to the ALCHEMIST-SCREEN (ALLIANCE A151216) trial prior to randomization.

    Lung: MK3475-867
    Sponsor: Merck
    Study: Lung: MK3475-867
    Cancer Stage: Stages I or IIA

    Description: A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Medically Inoperable Stages I or IIA NSCLC (KEYNOTE-867)

    Inclusions: 

    • Has NSCLC diagnosed by histology or cytology and confirmed as Stage I or IIA                                                            
    • Cannot undergo thoracic surgery due to existing medical illness  
    • Is able to receive SBRT
    • Has an ECOG Performance Status of 0, 1, or 2

    Exclusions: 

    • Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor                                                                                                                               
    • Has received prior radiotherapy to the thorax, including radiotherapy to the esophagus, mediastinum, or breast.

    Prior treatment: 

    • No prior therapy with an anti-PD-1, anti-PD-L1, anti PD-L2 agent or CTLA-4  

    Purpose:  

    • To compare the Event Free Survival following administration of Stereotactic Body Radiotherapy plus pembrolizumab versus Stereotactic Body Radiotherapy plus placebo  

    Basic Qualifications:

    • Has NSCLC diagnosed by histology or cytology and confirmed as Stage I or IIA                                                            
    • Cannot undergo thoracic surgery due to existing medical illness  

    Lung: 849-007
    Sponsor: Mirati
    Study: Lung: 849-007
    Cancer Stage: Metastatic or unresectable NSCLC

    Inclusions: 

    • NSCLC (squamous or nonsquamous) with KRAS G12C mutation
    • Unresectable or metastatic disease
    • Not a candidate for chemoradiation for locally advanced disease

    Exclusions: 

    • Prior systemic treatment for locally advanced or metastatic NSCLC

    Prior treatment: 

    • No prior treatment allowed

    Purpose: 

    • To evaluate the clinical activity of the MRTX849 study drug in combination with pembrolizumab administered in the first-line treatment setting to patients having NSCLC with KRAS G12C mutation

    Basic Qualifications: 

    • NSCLC (squamous or nonsquamous) with KRAS G12C mutation
    • Unresectable or metastatic disease

    Lung: 849-012
    Sponsor: Mirati
    Study: Lung: 849-012
    Cancer Stage: Advanced or metastatic disease

    Description: A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation

    Inclusions: 

    • NSCLC with KRAS G12C mutation
    • Receipt of prior treatment with a platinum and immune checkpoint inhibitor containing regimen for advanced or metastatic disease

    Exclusions: 

    • Active brain metastases
    • Prior treatment with an agent targeting KRAS G12C

    Prior treatment: 

    • Prior treatment with an immune checkpoint inhibitor and a platinum containing regimen required

    Purpose: 

    • To compare the efficacy of MRTX849 versus docetaxel in patients with NSCLC with KRAS G12C mutation

    Basic Qualifications:

    • NSCLC with KRAS G12C mutation 
    • Receipt of prior treatment with a platinum containing regimen and an immune checkpoint inhibitor

    Lung: BGB-317-A1217-301
    Sponsor: BeiGene
    Study: Lung: BGB-317-A1217-301
    Cancer Stage: NSCLC Stage III unresectable

    Description: Phase 3, Randomized, Open-Label Study to Compare Ociperlimab(BGB-A1217) Plus Tislelizumab (BGB-A317) Plus Concurrent Chemoradiotherapy (cCRT) Followed by Ociperlimab plus Tislelizumab Plus cCRT Followed by Tislelizumab vs cCRT followed by Durvalumab in Previously Untreated, Locally Advanced, Unresectable Non-Small Cell Lung Cancer (NCT# 04866017)

    Inclusions: 

    • Newly diagnosed, histologically confirmed, locally advanced, Stage III unresectable NSCLC

    Exclusions: 

    • NSCLC that harbors an EGFR-sensitizing mutation or ALK gene translocation

    Prior treatment: 

    Purpose: 

    • The primary objectives of this study is to compare progression free survival (PFS) and complete response rate (CRR) between participants treated with Ociperlimab plus tislelizumab plus Concurrent Chemoradiotherapy (cCRT) followed by Ociperlimab plus tislelizumab versus participants treated with tislelizumab plus Concurrent Chemoradiotherapy (cCRT) followed by tislelizumab versus participants treated with cCRT followed by durvalumab in previously untreated, locally advanced, unresectable non-small cell lung cancer (LA NSCLC)
    • The secondary objective of this study is to compare overall survival (OS) and PFS in programmed cell death protein ligand-1 (PD-L1) positive population between Arm A and C.

    Basic Qualifications:

    Lung: BGB-317-A1217-302
    Sponsor: BeiGene
    Study: Lung: BGB-317-A1217-302
    Cancer Stage: Previously untreated locally advanced unresectable or metastatic Non-Small Cell Lung Cancer

    Description: A Phase 3, Randomized, Double-Blind Study of BGB-A1217, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non -Small Cell Lung Cancer

    Inclusions: 

    • NSCLC that is not eligibel for curative surgery and/or definitive radiotherapy with or without chemoradiotherapy
    • No prior systemic treatment for metastatic NSCLC
    • Tumors with PD-L1 expression as centrally determined
    • Measurable lesions

    Exclusions: 

    • Known senstizing mutation in the EGFR gene or an ALK fusion oncogene
    • Active leptomeningeal disease or uncontrolled, untreated brain metastasis

    Prior treatment: 

    • No prior systemic treatment for metastatic NSCLC

    Purpose: 

    • This study compares progression-free survival and overall survival between arm A (BGB-A1217 in combination with Tislelizumab) and arm B (Pembrolizumab followed by placebo)

    Basic Qualifications:

  • Lymphoma and Blood Cancer

    Advanced Malignancies: ARCUS ARC-12
    Sponsor: ARCUS
    Study: Advanced Malignancies: ARCUS ARC-12
    Cancer Stage: Advanced

    Description: A phase 1/1b study to evaluate the safety and tolerability of AB308 in combination with AB122 in advanced malignancies

    Inclusions: 

    • Participants may have any pathologically confirmed solid tumor type for which no standard of care therapy exists
    • or pathologically confirmed NHL who are refractory or have relapsed on prior chemotherapy regimen and who have not received or are unable to receive allogenic stem cell transplant (ASCT) or adoptive cell transfer (ACT)
    • Participants may have received up to and including 5 lines of prior systemic anti-cancer therapies for advanced/recurrent and PD (an unlimited number of prior hormonal therapies) is allowed

    Exclusions: 

    • Treatment with systemic immunosuppressive medication
    • Prior treatment with an anti-TIGIT monoclonal antibody

    Prior treatment: 

    • Up to and including 5 lines of prior systemic anti-cancer therapies

    Purpose: 

    • To evaluate the safety, tolerability, PK, pharmacodynamics, and clinical activity of AB308 (anti-TIGIT inhibitor) in combination with zimberelimab (PD-1 inhibitor)

    Basic Qualifications: 

    DLBCL or CLL: KRT-232-2111
    Sponsor: Kartos
    Study: DLBCL or CLL: KRT-232-2111
    Cancer Stage: DLBCL or CLL

    Description:

    Inclusions: 

    • Cohort 1 (R/R DLBCL) a) Histologically confirmed diagnosis of de novo TP53wt ABC (nonGCB) or GCB DLBCL.  Phase 2: 25 or more subjects with non-GCB and    10 or more subjects with double-expressor lymphoma will be enrolled. b) R/R DLBCL after treatment with at least 2 prior lines of systemic therapy or at least 1 prior line of systemic therapy in subjects who are ineligible for hematopoietic stem cell transplantation c) At least 1 measurable site of disease 
    • Cohort 2 (R/R CLL) d) Histologically confirmed diagnosis of TP53wt CLL according to iwCLL criteria. e) Previously treated with at least 1 prior regimen according to current guidelines. f) Active disease meeting at least 1 of the iwCLL 2008 criteria for requiring treatment 

    Exclusions: 

    • Subjects with a history of central nervous system involvement.
    • Any recent prior therapy meeting one or more of the following criteria: a) Concurrent anticancer treatment, such as chemotherapy, cytoreductive therapy, immune therapy, or cytokine therapy: i. DLBCL: Within 14 days prior to the first dose of study treatment. ii. CLL: Within 28 days prior to the first dose of study treatment
    • Allogeneic stem cell transplant within the last 6 months

    Prior treatment: 

    • Yes, prior treatment is required

    Purpose: 

    • To determine the KRT-232 maximum tolerated dose and safety and tolerability of KRT-232 in combination with acalabrutinib

    Basic Qualifications:

    • Cohort 1 (R/R DLBCL) a) Histologically confirmed diagnosis of de novo TP53wt ABC (nonGCB) or GCB DLBCL.  Phase 2: 25 or more subjects with non-GCB and    10 or more subjects with double-expressor lymphoma will be enrolled. b) R/R DLBCL after treatment with at least 2 prior lines of systemic therapy or at least 1 prior line of systemic therapy in subjects who are ineligible for hematopoietic stem cell transplantation c) At least 1 measurable site of disease 
    • Cohort 2 (R/R CLL) d) Histologically confirmed diagnosis of TP53wt CLL according to iwCLL criteria. e) Previously treated with at least 1 prior regimen according to current guidelines. f) Active disease meeting at least 1 of the iwCLL 2008 criteria for requiring treatment 

    T-Cell Lymphoma: IPH4102-102
    Sponsor: Innate Pharma
    Study: T-Cell Lymphoma: IPH4102-102
    Cancer Stage: Relapsed

    Description: A phase Ib trial evaluating the safety and efficacy of lacutamab in patients with relapse peripheral T-cell lymphoma that express KIR3DL2

    Inclusions: 

    • Patients should have received at least one prior systemic therapy
    • Patients should have had a complete response to first line systemic therapy and / or relapsed or progressed no sooner than 6 months after finishing first line therapy
    • KIR3DL2 expression
    • Presence of at least 1 target lesion

    Exclusions: 

    • Treatment with > 3 lines of systemic therapies prior to enrollment. Consolidation therapy
      including stem cell transplant is not considered a line of therapy

    Prior treatment: 

    • Patients should have received at least one prior systemic therapy

    Purpose: 

    • To Evaluate the safety and efficacy of lacutamab

    Basic Qualifications:

    B Cell malignancies: ICP-CL-0107
    Sponsor: InnoCare Pharma
    Study: B Cell malignancies: ICP-CL-0107
    Cancer Stage: Relapsed

    Description: A Phase I/II Open-Label Study of a Novel Bruton’s Tyrosine Kinase Inhibitor, Orelabrutinib, in Patients with B-Cell Malignancies

    Inclusions: 

    • Patients with histologically confirmed relapsed or refractory B-cell malignancies, including only patients
      with Grades 1-3a FL, MZL, MCL, and CLL/SLL
    • Must have received ≥1 or ≤ 4 prior therapies with documented failure to achieve at least a partial
      response or disease progression after the most recent systemic treatment

    Exclusions: 

    • Prior treatment with systemic immunotherapeutic agents, including but not limited to cytokine therapy
      and anti-CTLA4, anti-PD1 and anti-PDL1 therapeutic antibodies, within 12 weeks
    • Treatment with any chemotherapeutic agent, or treatment with any other investigational therapies
      including but not limited to anti-cancer agent (defined as treatment for which there is currently no
      regulatory authority approved indication) within 4 weeks prior to first dose of orelabrutinib

    Prior treatment: 

    • Must have received ≥1 or ≤ 4 prior therapies

    Purpose: 

    • Despite the recent advancements in survival with the introduction of chimeric anti-CD20 monoclonal antibody therapy, approximately 50% of patients with non-hodgkin’s lymphoma (NHL) will not sustain a durable response following standard of care treatment. Thus, there remains a continuous need of having safer and more effective therapies for those patients.

    Basic Qualifications:

  • Melanoma and Skin Cancer

    Advanced Malignancies: Mirati 516-010
    Sponsor: Mirati Therapeutics
    Study: 516-010
    Cancer Stage: Advanced Solid Metastatic Malignancies

    Description: A Two-cohort, Two-part, Phase 1, Multicenter, Open-label, Fixed-sequence, Drug-Drug Interaction and QTc Assessments of Sitravatinib Followed by Combination Treatment with Nivolumab in Patients with Advanced Solid Malignancies (NCT# 04887194)

    Inclusions: 

    • Histologically or cytologically confirmed diagnosis of unresectable advanced/metastatic
      solid tumor malignancy
    • No available treatment with curative intent, or No available standard-of-care (SOC) treatment or patient is ineligible or declines treatment

    Exclusions:

    Prior treatment:

    Purpose: 

    • This is a two-cohort, two-part, Phase 1, multicenter, open-label, nonrandomized, fixed-sequence study in patients with advanced/metastatic solid tumors. The DDI cohort, Part 1, is designed to evaluate the potential for drug interactions with sitravatinib monotherapy and to collect ECG data for QTc analysis (CCC is not participating in the DDI cohort). The QTc cohort, Part 1, is designed to evaluate the effect of sitravatinib on QTc. Concentration and QTc data collected from both DDI and QTc cohorts will be used for C-QTc modeling. Part 2 allows for patients from both cohorts to continue sitravatinib treatment with the addition of the checkpoint inhibitor nivolumab.

    Basic Qualifications:

    Advanced Malignancies: ARCUS ARC-12
    Sponsor: ARCUS
    Study: Advanced Malignancies: ARCUS ARC-12
    Cancer Stage: Advanced

    Description: A phase 1/1b study to evaluate the safety and tolerability of AB308 in combination with AB122 in advanced malignancies

    Inclusions: 

    • Participants may have any pathologically confirmed solid tumor type for which no standard of care therapy exists
    • or pathologically confirmed NHL who are refractory or have relapsed on prior chemotherapy regimen and who have not received or are unable to receive allogenic stem cell transplant (ASCT) or adoptive cell transfer (ACT)
    • Participants may have received up to and including 5 lines of prior systemic anti-cancer therapies for advanced/recurrent and PD (an unlimited number of prior hormonal therapies) is allowed

    Exclusions: 

    • Treatment with systemic immunosuppressive medication
    • Prior treatment with an anti-TIGIT monoclonal antibody

    Prior treatment: 

    • Up to and including 5 lines of prior systemic anti-cancer therapies

    Purpose: 

    • To evaluate the safety, tolerability, PK, pharmacodynamics, and clinical activity of AB308 (anti-TIGIT inhibitor) in combination with zimberelimab (PD-1 inhibitor)

    Basic Qualifications: 

  • Pancreatic Cancer

    Advanced Malignancies: Mirati 516-010
    Sponsor: Mirati Therapeutics
    Study: 516-010
    Cancer Stage: Advanced Solid Metastatic Malignancies

    Description: A Two-cohort, Two-part, Phase 1, Multicenter, Open-label, Fixed-sequence, Drug-Drug Interaction and QTc Assessments of Sitravatinib Followed by Combination Treatment with Nivolumab in Patients with Advanced Solid Malignancies (NCT# 04887194)

    Inclusions: 

    • Histologically or cytologically confirmed diagnosis of unresectable advanced/metastatic
      solid tumor malignancy
    • No available treatment with curative intent, or No available standard-of-care (SOC) treatment or patient is ineligible or declines treatment

    Exclusions:

    Prior treatment:

    Purpose: 

    • This is a two-cohort, two-part, Phase 1, multicenter, open-label, nonrandomized, fixed-sequence study in patients with advanced/metastatic solid tumors. The DDI cohort, Part 1, is designed to evaluate the potential for drug interactions with sitravatinib monotherapy and to collect ECG data for QTc analysis (CCC is not participating in the DDI cohort). The QTc cohort, Part 1, is designed to evaluate the effect of sitravatinib on QTc. Concentration and QTc data collected from both DDI and QTc cohorts will be used for C-QTc modeling. Part 2 allows for patients from both cohorts to continue sitravatinib treatment with the addition of the checkpoint inhibitor nivolumab.

    Basic Qualifications:

    Pancreatic: PT049
    Sponsor: Xbiotech USA Inc.
    Study: Pancreatic: PT049
    Cancer Stage: Advanced Pancreatic Cancer

    Description: A Phase I/II randomized, double-blind, placebo-controlled trial (1-BETTER) examining XB2001 (anti-IL-1? True Human antibody) in combination with ONIVYDE + 5-FU/LV (+folinic acid) in advanced pancreatic cancer

    Inclusions: 

    • pancreatic adenocarcinoma of exocrine pancreas that is metastatic, unresectable, or recurrent

    Exclusions: 

    • Evidence of brain metastases
    • Prior whole brain radiation therapy

    Prior treatment: 

    Purpose: This trial will include 2 portions (phase 1 and phase 2):

    Phase 1:
    • The first portion will be a Phase I, open label, dose escalation study to investigate the safety and tolerability of XB2001 in at least 9 subjects as measured by Dose-Limiting Toxicity (DLT), in combination with ONIVYDE + LV + 5-FU chemotherapy regimen as second or third line treatment in subjects with advanced pancreatic cancer and to determine the recommended dose for the subsequent Phase 2 study.
    • The phase 2 portion will be implemented following the completion of the Phase I portion and declaration of safety with respect to the maximum tolerated dose (MTD) or the maximum dose studied if the MTD is not observed in phase I portion.
    Phase 2:
    • The target enrollment in the phase 2 portion is 60 subjects which will be randomized on a 1:1 basis to XB2001 plus ONIVYDE + LV + 5-FU (Arm 1) or placebo plus ONIVYDE + LV + 5-FU (Arm 2).

    Basic Qualifications:

  • Prostate Cancer

    Advanced Malignancies: Mirati 516-010
    Sponsor: Mirati Therapeutics
    Study: 516-010
    Cancer Stage: Advanced Solid Metastatic Malignancies

    Description: A Two-cohort, Two-part, Phase 1, Multicenter, Open-label, Fixed-sequence, Drug-Drug Interaction and QTc Assessments of Sitravatinib Followed by Combination Treatment with Nivolumab in Patients with Advanced Solid Malignancies (NCT# 04887194)

    Inclusions: 

    • Histologically or cytologically confirmed diagnosis of unresectable advanced/metastatic
      solid tumor malignancy
    • No available treatment with curative intent, or No available standard-of-care (SOC) treatment or patient is ineligible or declines treatment

    Exclusions:

    Prior treatment:

    Purpose: 

    • This is a two-cohort, two-part, Phase 1, multicenter, open-label, nonrandomized, fixed-sequence study in patients with advanced/metastatic solid tumors. The DDI cohort, Part 1, is designed to evaluate the potential for drug interactions with sitravatinib monotherapy and to collect ECG data for QTc analysis (CCC is not participating in the DDI cohort). The QTc cohort, Part 1, is designed to evaluate the effect of sitravatinib on QTc. Concentration and QTc data collected from both DDI and QTc cohorts will be used for C-QTc modeling. Part 2 allows for patients from both cohorts to continue sitravatinib treatment with the addition of the checkpoint inhibitor nivolumab.

    Basic Qualifications:

    Advanced Malignancies: ARCUS ARC-12
    Sponsor: ARCUS
    Study: Advanced Malignancies: ARCUS ARC-12
    Cancer Stage: Advanced

    Description: A phase 1/1b study to evaluate the safety and tolerability of AB308 in combination with AB122 in advanced malignancies

    Inclusions: 

    • Participants may have any pathologically confirmed solid tumor type for which no standard of care therapy exists
    • or pathologically confirmed NHL who are refractory or have relapsed on prior chemotherapy regimen and who have not received or are unable to receive allogenic stem cell transplant (ASCT) or adoptive cell transfer (ACT)
    • Participants may have received up to and including 5 lines of prior systemic anti-cancer therapies for advanced/recurrent and PD (an unlimited number of prior hormonal therapies) is allowed

    Exclusions: 

    • Treatment with systemic immunosuppressive medication
    • Prior treatment with an anti-TIGIT monoclonal antibody

    Prior treatment: 

    • Up to and including 5 lines of prior systemic anti-cancer therapies

    Purpose: 

    • To evaluate the safety, tolerability, PK, pharmacodynamics, and clinical activity of AB308 (anti-TIGIT inhibitor) in combination with zimberelimab (PD-1 inhibitor)

    Basic Qualifications: 

  • Sarcoma Cancer

    Advanced Malignancies: Mirati 516-010
    Sponsor: Mirati Therapeutics
    Study: 516-010
    Cancer Stage: Advanced Solid Metastatic Malignancies

    Description: A Two-cohort, Two-part, Phase 1, Multicenter, Open-label, Fixed-sequence, Drug-Drug Interaction and QTc Assessments of Sitravatinib Followed by Combination Treatment with Nivolumab in Patients with Advanced Solid Malignancies (NCT# 04887194)

    Inclusions: 

    • Histologically or cytologically confirmed diagnosis of unresectable advanced/metastatic
      solid tumor malignancy
    • No available treatment with curative intent, or No available standard-of-care (SOC) treatment or patient is ineligible or declines treatment

    Exclusions:

    Prior treatment:

    Purpose: 

    • This is a two-cohort, two-part, Phase 1, multicenter, open-label, nonrandomized, fixed-sequence study in patients with advanced/metastatic solid tumors. The DDI cohort, Part 1, is designed to evaluate the potential for drug interactions with sitravatinib monotherapy and to collect ECG data for QTc analysis (CCC is not participating in the DDI cohort). The QTc cohort, Part 1, is designed to evaluate the effect of sitravatinib on QTc. Concentration and QTc data collected from both DDI and QTc cohorts will be used for C-QTc modeling. Part 2 allows for patients from both cohorts to continue sitravatinib treatment with the addition of the checkpoint inhibitor nivolumab.

    Basic Qualifications:

  • All Other Cancers

    All Other Cancers: CHEM-01
    Sponsor: Chemo Mouthpiece
    Study: All Other Cancers: CHEM-01
    Cancer Stage: 

    Description:


    Inclusions: 

    • Age 18-80 years
    • Planned to receive at least 2 cycles of infused stomatotoxic chemotherapy regimens such as: ï‚· CMF (cyclophosphamide (Cytoxan), methotrexate, 5-FU) ï‚· Standard AC+T regimen (doxorubicin (Adriamycin), cyclophosphamide (Cytoxan), Taxane [paclitaxel (Taxol) or docetaxel (Taxotere)]) or any combination of two or more components (e.g., ACT, TAC, TA, AT, AC) ï‚· ABVD (doxorubicin (Adriamycin), bleomycin, vinblastine, dacarbazine) ï‚· FOLFIRI (irinotecan, 5-FU, leucovorin) ï‚·
    • Any other 5-FU-based regimen (excluding FOLFOX)

    Exclusions: 

    • Receiving any oxaliplatin-containing chemotherapy regimen, such as FOLFOX
    • Concurrent radiotherapy
    • Unable or unwilling to complete study assessments
    • Unable or unwilling to avoid using ice chips
    • Known allergy to silicone

    Prior treatment: 

    • Not required

    Purpose: 

    • To Assess the Efficacy of a Cryotherapy Device Versus Best Supportive Oral Care in Mitigating Symptoms of Oral Mucositis in Patients Receiving Chemotherapy for the Treatment of Cancer

    Basic Qualifications 

    • Planned to receive at least 2 cycles of infused stomatotoxic chemotherapy regimens such as: ï‚· CMF (cyclophosphamide (Cytoxan), methotrexate, 5-FU) ï‚· Standard AC+T regimen (doxorubicin (Adriamycin), cyclophosphamide (Cytoxan), Taxane [paclitaxel (Taxol) or docetaxel (Taxotere)]) or any combination of two or more components (e.g., ACT, TAC, TA, AT, AC) ï‚· ABVD (doxorubicin (Adriamycin), bleomycin, vinblastine, dacarbazine) ï‚· FOLFIRI (irinotecan, 5-FU, leucovorin)
    • Any other 5-FU-based regimen (excluding FOLFOX)

    High risk of Ovarian Cancer Surgical Study: NRG- CC008
    Sponsor: NRG Oncology
    Study: Ovarian Cancer Risk: NRG- CC008
    Cancer Stage: None

    Description: A study to compare two surgical procedures in women with BRCA1 mutations to assess reduced risk of Ovarian Cancer  

    Inclusions: 

    • Women 35-50 years of age, inclusive
    • At least one intact ovary and fallopian tube

    Exclusions: 

    • A history of any prior cancer and received chemotherapy within the past 12 months
    • hormonal therapy in the past 90 days
    • or radiotherapy to abdomen or pelvis at any prior time                                                                                                                                                        

    Prior treatment: 

    • No prior treatment within the past 12 months

    Purpose: 

    • A study to compare two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) in women with BRCA1 mutations to assess reduced risk of Ovarian Cancer

    Basic Qualifications: 

    • Women 35-50 years of age with a high risk of ovarian cancer with at least one intact ovary and fallopian tube undergoing surgery

Goshen Health News & Articles

Browse more articles